Novartis Showcases Remibrutinib And Cosentyx® Data At Major Allergy And Dermatology Meetings

Novartis has announced plans to present data from 17 abstracts, including investigator-initiated trials, at two major medical meetings: the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress, as well as the 2025 American Academy of Dermatology (AAD) Annual Meeting. The data span its immunology portfolio, focusing on treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). 

 Angelika Jahreis, Global Head, Development, Immunology, Novartis, said in a statement, “Conditions like CSU and HS are more than just skin deep, often having a profound impact on patients' daily lives and activities. These data at AAAAI and AAD highlight our continued commitment to reimagine medicine and address treatment gaps for people with immune-mediated diseases. We are particularly excited about the potential for remibrutinib as a novel oral treatment for patients with CSU who remain symptomatic on antihistamines.”

Key presentations will feature findings from the Phase III REMIX-1 and REMIX-2 studies on remibrutinib, an investigational therapy for CSU. These studies provide insights into long-term urticaria control, sleep improvement, and patient activity levels. Additionally, Novartis will present long-term data from the Phase III SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in HS patients, along with patient-reported outcomes from a Phase II trial assessing remibrutinib in HS. 

Results from CSU study patients at the CSU will help Novartis submit their regulatory applications in the first half of 2025 to establish remibrutinib as a new therapeutic option. Remibrutinib explores additional therapeutic uses at Novartis, and researchers investigate it for chronic inducible urticaria (CIndU), HS, and food allergies, alongside its promising results in CSU.